Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEDCO's ANTI-ARRHYTHMIC ADENOCARD RECOMMENDED FOR APPROVAL BY FDA COMMITTEE

Executive Summary

FDA's Cardio-Renal Drugs Advisory Committee unanimously recommended approval for Medco's Adenocard (adenosine) in the treatment of paroxysmal supraventricular tachycardia at the panel's May 4 meeting. The committee found that data presented by Medco Research raised "no safety concerns" in using Adenocard in the termination of arrhythmias. However, committee reviewer Jeremy Ruskin, MD, Massachusetts General Hospital, remarked "if the drug were for prophylaxis, one could raise major concerns [about the data]." The committee also recommended that Adenocard therapy begin with a dose of 6 mg, increasing to a maximum dose of 12 mg in dosing intervals of two minutes. In one study that compared a 12 mg dose of Adenocard to a 7.5 mg dose of verapamil, Adenocard was found to have similar efficacy of about 95%. At 6 mg, Adenocard had only 60% efficacy compared to 80% for 5 mg of verapamil. Adenocard's time to conversion, however, was shorter than verapamil's -- 30 minutes versus 170 minutes. Medco has licensed manufacturing and marketing rights for Adenocard in the U.S. and Canada to Lyphomed and to Sanofi-France for the rest of the world. Medco has adenosine in development for at least seven other indications, including adjuvant to treatment of brain tumors (Phase II), prevention of myocardial reperfusion damage (Phase II), and as a substitute for exercise stress testing in diagnosis of coronary artery disease (Phase III).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015556

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel